LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer

Table 1 Correlation of maternally expressed gene 3 levels and clinicopathological features in colorectal cancer

Clinical features	Cases	Serum MEG3 expression	P value
Age in yr			0. 956
≥ 60	54	0.678 ± 0.013
< 60	72	0.679± 0.043
Gender			0.400
Male	85	0.665 ± 0.032
Female	41	0.696 ± 0.038
Tumor site			0.843
Colon	58	0.671 ± 0.044
Rectum	68	0.676 ± 0.032
Tumor size in cm			0.001
≥ 5	43	0.748 ± 0.031
< 5	83	0.567 ± 0.039
pT, TNM			0.098
T1+T2	93	0.617 ± 0.025
T3+T4	33	0.693 ± 0.019
Lymph node metastasis			0.236
Positive	71	0.717 ± 0.046
Negative	55	0.662 ± 0.034
Clinical stage, TNM
III	72	0.867 ± 0.049	0.001
I+II	54	0.562 ± 0.018
Pathological differentiation
Well/moderate	59	0.665 ± 0.050	0.322
Poor	67	0.710 ± 0.032

TNM: Tumor node metastasis; MEG3: Maternally expressed gene 3.